Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 is a rare inflammatory condition that usually begins before birth or in the first weeks of life. Babies and children living with Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 can have fevers, rash, swelling, bowel problems, and poor growth, along with signs of inflammation in several organs. It is usually a lifelong condition, and not everyone will have the same experience. Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 can be life threatening, especially when inflammation is severe or treatment is delayed. Treatment focuses on controlling inflammation with specialist care, supportive treatment, and in some cases targeted medicines, and early symptoms of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 need urgent medical attention.
How many people live with Neonatal-onset severe multisystemic autoinflammatory disease with increased il18?
There are no reliable published estimates for how many people live with neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 worldwide or in the United States. It is considered ultra-rare, and the medical literature describes only a very small number of affected people rather than a population-based count.
Overview
Neonatal-onset severe multisystemic autoinflammatory disease with increased il18Symptoms
Neonatal-onset severe multisystemic autoinflammatory disease with increased il18 often starts at birth. Features include ongoing fevers, widespread rash, severe diarrhea, poor feeding, and slow growth. Many babies also have enlarged liver or spleen and serious inflammation in several organs.
Outlook and prognosis
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 often starts in the first weeks of life and can be life-threatening without rapid specialist care. Outlook varies, but early diagnosis, close monitoring, and treatment can improve inflammation control and support growth and organ health.
Causes and risk factors
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 is caused by a harmful change in the NLRC4 gene, often new but sometimes inherited. Family history raises risk; lifestyle or environmental factors do not cause it, though infections can worsen flares.
Genetic influences
Genetics are central to Neonatal-onset severe multisystemic autoinflammatory disease with increased il18, which is caused by harmful changes in a single gene. These genetic variations disrupt immune control and are key for confirming the diagnosis and family counseling.
Diagnosis
Diagnosis of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is based on clinical features soon after birth, blood tests showing marked inflammation, and genetic tests. Doctors may also use imaging or organ-focused tests to check multisystem involvement.
Treatment and drugs
Treatment for neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 usually centers on expert immune-suppressing medicines, often biologic drugs. Many also need close monitoring, nutritional support, and fast treatment of infections and organ complications.
Symptoms
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 usually shows up in the first days, weeks, or months of life with intense whole-body inflammation. The early features of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 often affect the skin, gut, liver, blood, and joints rather than just one body part. Features vary from person to person and can change over time.
Repeated fevers are common and can begin in the newborn period. During a flare, babies may seem very ill, sleepy, fussy, or hard to feed.
Many people with this condition develop a red, blotchy, or hive-like rash that may come and go with inflammation. The skin can look irritated even when there is no infection.
Severe diarrhea, vomiting, belly swelling, or blood in the stool can be major early features. Feeding may be difficult, and babies can become dehydrated quickly.
Ongoing inflammation and feeding problems often make it hard to gain weight well. Some infants also grow more slowly in length and seem weaker than expected.
How people usually first notice Neonatal-onset severe multisystemic autoinflammatory disease with increased il18?
How Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is first noticed often begins in the first days or weeks of life, when a baby develops repeated fevers, a widespread rash, and signs of severe inflammation that do not fit a typical infection. Families and doctors may also notice poor feeding, diarrhea, irritability, swelling, or trouble gaining weight, while blood tests often show very high inflammation markers and markedly increased IL-18, an immune system signaling protein. Because this is a rare genetic autoinflammatory condition, the first signs of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 usually lead to urgent medical evaluation and, over time, genetic testing to confirm the diagnosis.
Types of Neonatal-onset severe multisystemic autoinflammatory disease with increased il18
No distinct types of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 are widely recognized.
Can I slow down the onset of symptoms?
No, at this time there is no good evidence that lifestyle changes or medical treatment can meaningfully delay the onset of neonatal-onset severe multisystemic autoinflammatory disease with increased IL18, because it is a very rare inherited inflammatory condition that usually begins around birth or in the first days of life. Things like diet, exercise, sleep, or supplements have not been shown to prevent it, and while research is ongoing into treatments that calm the immune system, these are used to manage symptoms after they start rather than to stop the disease from beginning. If this condition is known or suspected in a family, early genetic counseling and prompt newborn specialist care can help with faster diagnosis and treatment, which may improve day-to-day outcomes even though it does not prevent the condition.
What genetics can tell you about symptoms
Yes. In this condition, a disease-causing genetic change can strongly shape the symptom pattern by turning on the body’s inflammation pathways too much, which helps explain why many living with it become ill in the newborn period and can have severe whole-body inflammation, fever, gut problems, and very high IL-18 levels. The exact genetic change may influence which symptoms stand out most, how severe they are, and how early they begin, although there can still be some variation even among people in the same family.
Causes and risk factors
The cause of neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 is usually a harmful change in the NLRC4 gene. This change makes part of the immune system too active, which leads to very high IL-18 and severe inflammation. It can be inherited from a parent or can happen for the first time in the child, so family history is one important risk factor. Infections and other immune stressors may trigger or worsen flares, and risk can vary widely from person to person. Lifestyle does not cause this condition, but good nutrition and regular medical care can help support overall health.
What are the most common causes or risk factors?
This condition is usually caused by a harmful change in a gene called NLRC4, either passed down from a parent or starting for the first time in the child, which makes the body’s defense system stay too active from birth and leads to very high levels of an inflammation signal called IL-18. There are no well-known lifestyle or environmental risk factors. In some children, infections or other immune stress can trigger or worsen flares, but they are not the root cause.
Environmental and biological risk factors
For Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18, no clear environmental or non-genetic biological risk factors have been confirmed. If you are looking for environmental risk factors for Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18, current evidence is very limited. Researchers are still exploring how outside influences interact with our inner biology.
Genetic risk factors
Most cases of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 are linked to a harmful change in CDC42, a gene involved in controlling inflammation inside cells. When families ask about the genetic causes of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18, this is the main cause identified so far. The variant is often new in the child, but it can sometimes be passed on in an autosomal dominant pattern, meaning one altered copy is enough to cause disease. Because this disorder is very rare, genetic testing is usually needed to confirm the cause and clarify recurrence risk for the family.
CDC42 variant: The main known cause is a harmful change in CDC42, a gene that helps keep inflammation under control. When this gene is altered, immune signals can become overactive and IL-18 levels often rise sharply.
Tail-end changes: Most reported cases involve a very specific single-letter change near the end of the CDC42 gene. Changes in this region seem especially likely to cause the severe newborn form.
New mutation: In many families, the variant is de novo, which means it happened for the first time in the child. Parents usually did nothing to cause this, and they often do not carry the change in their blood.
Dominant inheritance: If a parent does carry the same disease-causing variant, each pregnancy has a 1 in 2, or 50%, chance of inheriting it. Rarely, a parent can have the variant in only some egg or sperm cells, so a future pregnancy may still be at risk even when the parent's blood test is normal.
Lifestyle risk factors
Lifestyle habits do not cause Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18, but they can influence how often symptoms flare, how well the body tolerates inflammation, and how complications are managed. Because this condition can affect several organs and may involve severe inflammation from early life, day-to-day routines should be tailored with the treating specialist team. In practice, how lifestyle affects Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is mainly through infection prevention, nutrition, activity pacing, and careful support during illness.
Everyday infections can trigger major inflammatory worsening in people with this condition. Reducing exposure through good hand hygiene, avoiding sick contacts when possible, and following the care team's vaccine plan may lower the chance of illness-related flares.
Poor intake, feeding difficulties, or undernutrition can make it harder to cope with chronic inflammation and can impair growth and recovery. Individualized nutrition plans, including adequate calories, protein, and fluids, may help maintain strength and support healing.
Vomiting, diarrhea, fever, or poor feeding can lead to dehydration quickly during inflammatory episodes. Keeping hydration steady can support circulation, kidney function, and overall stability, especially during acute illness.
Lifestyle risk factors for Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 include pushing through fatigue or illness beyond the body's limits. Gentle movement and physical therapy can help preserve mobility and conditioning, but activity often needs to be adjusted during flares.
Risk prevention
For neonatal-onset severe multisystemic autoinflammatory disease with increased IL18, there is no known way to prevent the condition itself because it starts from an underlying genetic change. Prevention is mainly about lowering the chance of flares, organ damage, infections, and other complications through close medical care from infancy onward. Different people need different prevention strategies—there’s no single formula. Early, steady follow-up can make a real difference in day-to-day comfort and long-term health.
Regular follow-up with a pediatric immunology or rheumatology team can help catch inflammation early and adjust treatment before problems build. This is one of the most important ways to prevent complications in neonatal-onset severe multisystemic autoinflammatory disease with increased IL18.
Anti-inflammatory or immune-targeting medicines work best when taken exactly as prescribed. Stopping them suddenly or missing doses can raise the risk of severe flares and organ injury.
Infections can trigger worsening symptoms, so handwashing, avoiding sick contacts when possible, and discussing vaccines with the care team are important. Doctors may adjust vaccine plans depending on the treatments being used and how the immune system is working.
Regular blood tests and checks of the liver, blood counts, growth, and other organs can show silent inflammation before a child seems obviously unwell. This is especially helpful when the early symptoms of neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 are hard to separate from common childhood illnesses.
Can you prevent Neonatal-onset severe multisystemic autoinflammatory disease with increased il18?
In most cases, no. This very rare condition usually happens because of a change in a gene that affects how the body's defense system reacts, so there is no proven way to prevent it. If it has happened in your family before, genetic counseling may help you understand the chances in a future pregnancy, but it cannot fully prevent the condition.
Transmission
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 is not an infection, so it is not contagious and does not spread through coughing, touching, food, or everyday contact. Instead, how Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 is inherited usually relates to a harmful change in a gene that helps control inflammation.
In many families, this gene change can be passed from a parent to a child in what is called an autosomal dominant pattern, meaning each pregnancy carries a 1 in 2, or 50%, chance of passing it on. Some babies develop Neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 because the gene change happened for the first time in them, even when neither parent has the condition.
When to test your genes
Consider genetic testing early, especially in a newborn or infant with severe inflammation, recurrent fevers, rash, diarrhea or enterocolitis, very high IL-18, or episodes of macrophage activation syndrome. Testing also matters if there is a family history, because a confirmed diagnosis can guide monitoring and targeted treatment.
Diagnosis
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is usually suspected very early in life because a baby has ongoing inflammation affecting more than one part of the body, rather than a single isolated problem. Doctors usually begin by looking closely at the pattern of symptoms over time, such as repeated fevers, rash, liver or gut inflammation, and poor growth. Because this is a rare inherited immune condition, the diagnosis of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 often combines exam findings, blood tests, and genetic testing. Some diagnoses are clear after a single visit, while others take more time.
Doctors look at when symptoms began and which organs are involved, especially if inflammation started in the newborn period. A combination of persistent fevers, rash, enlarged liver or spleen, diarrhea, poor weight gain, and other inflammatory problems can raise strong concern for this condition.
Blood work usually shows clear signs of inflammation, such as raised inflammatory markers, anemia, or changes in blood cell counts. Doctors also measure IL18 and may check other immune signals to support the diagnosis and help rule out other causes of severe inflammation.
Since severe infection in a newborn can look similar at first, doctors often test for bacteria, viruses, and other common triggers. These tests help make sure the inflammation is not being caused by a treatable infection.
The genetic diagnosis of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is made by finding a disease-causing change in the responsible gene. This confirms that the immune system problem is inherited rather than caused by infection, injury, or another inflammatory disease.
How is Neonatal-onset severe multisystemic autoinflammatory disease with increased il18 diagnosed?
Doctors diagnose this condition by looking at the whole picture: severe inflammation starting in the newborn period, symptoms affecting several parts of the body, and blood tests showing strong inflammation with very high IL-18, which is an immune system signal. They also do tests to rule out infections and other conditions that can look similar, and genetic testing may help confirm the diagnosis by finding the gene change linked to the disease.
Stages of Neonatal-onset severe multisystemic autoinflammatory disease with increased il18
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 does not have defined progression stages. This is because it is a rare inflammatory condition that is identified by its pattern of symptoms and test results, rather than by a clear step-by-step worsening over time. Doctors usually start with a conversation about when symptoms began, such as fevers, rash, joint swelling, or signs of inflammation affecting more than one part of the body, including the early symptoms of neonatal-onset severe multisystemic autoinflammatory disease with increased IL18. Monitoring often includes blood tests for inflammation, IL18 levels, and careful follow-up with specialists to check how the condition is affecting daily life and different organs.
Outlook and prognosis
The outlook for neonatal-onset severe multisystemic autoinflammatory disease with increased il18 is often guarded, especially in infancy, because affected babies can develop recurrent or persistent hyperinflammation, severe enterocolitis, macrophage activation syndrome, growth failure, and multi-organ complications. Prognosis varies widely, with some children improving when the disease is recognized early and treated aggressively with targeted anti-inflammatory therapy and intensive supportive care, while others continue to have chronic inflammation and significant disability. Episodes of macrophage activation syndrome can be rapidly life-threatening and are a major driver of poor outcomes. Reported mortality is increased in the most severe neonatal cases, particularly when diagnosis is delayed or inflammation is not adequately controlled. Long-term survivors may still face ongoing medical needs, including nutritional support, monitoring for organ damage, and repeated adjustments in immunomodulatory treatment. Early care from specialists in immunology, rheumatology, gastroenterology, and intensive care offers the best chance of improving survival and quality of life.
Long-term effects
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 can affect many parts of the body over time, so the long-term picture often depends on how early and how strongly inflammation has been active. Many living with this condition have ongoing health effects involving growth, the gut, joints, skin, blood counts, and sometimes the liver or nervous system. Long-term effects vary widely, and even with the same diagnosis, children can have different needs as they grow into adolescence and adulthood.
Ongoing inflammation can make it harder for children with Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 to gain weight and grow as expected. Over time, this can mean short stature, delayed physical development, or a need for close monitoring through childhood.
Long-term bowel inflammation may lead to chronic diarrhea, poor nutrient absorption, belly pain, and feeding difficulties. In some children, the early symptoms of Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 continue into later childhood as persistent intestinal disease.
Repeated or ongoing inflammation in the joints can limit movement and cause stiffness that affects walking, play, or daily tasks. Over years, some may develop lasting joint damage or reduced range of motion.
Many people with this condition have recurring rashes or other skin inflammation that can continue over time. Some effects may be mainly visible on the skin, while others can reflect deeper ongoing inflammation elsewhere in the body.
How is it to live with Neonatal-onset severe multisystemic autoinflammatory disease with increased il18?
Living with neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 often means dealing from the very start of life with repeated inflammation that can affect several parts of the body at once, so daily life may revolve around symptoms, medical visits, blood tests, and careful monitoring for flares or complications. For many living with this condition, energy, growth, comfort, and day-to-day routines can be disrupted, and families often need to adapt work, sleep, travel, and childcare around unpredictable illness. This can be demanding for parents, siblings, and other caregivers, but with specialist care, close follow-up, and practical support, many families find ways to build steadier routines and a strong sense of control.
Treatment and drugs
For people living with Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18, treatment usually focuses on calming the overactive inflammation quickly, protecting organs, and preventing flare-ups over time. Care often includes targeted anti-inflammatory medicines, corticosteroids, and close monitoring in the hospital when symptoms are severe, especially in babies and young children who may be very ill early on. Because this is a rare and serious condition, doctors often tailor treatment to the child’s symptoms, lab results, and overall organ involvement, and some may need care from several specialists at once. Not every treatment works the same way for every person, so the plan may need to change if inflammation stays active or side effects become a concern. In some cases, supportive treatments such as fluids, nutrition support, or treatment for complications are also an important part of care.
Can you cure Neonatal-onset severe multisystemic autoinflammatory disease with increased il18?
No, there is no cure right now for neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18, a rare condition where the immune system is overactive from birth. Treatment aims to calm inflammation, ease symptoms, and lower the risk of serious problems such as damage to organs. Many living with this condition need ongoing specialist care and medicines that reduce inflammation, and how well these help can vary from person to person.
Non-drug treatment
Daily care for Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 often goes far beyond medicines, because ongoing inflammation can affect movement, feeding, hearing, vision, growth, and development. Managing this condition often means working with several specialists so problems are found early and daily life stays as comfortable and active as possible. Non-drug treatments do not replace medical treatment, but they can ease symptoms, support development, and help families handle the condition at home and at school.
Regular follow-up with rheumatology, neurology, eye, ear, and rehabilitation specialists helps track how the disease is affecting different parts of the body. This can make it easier to catch hearing loss, vision changes, joint problems, or developmental delays early.
Gentle stretching, strengthening, and guided movement can help protect joint motion and reduce stiffness in children who have pain or swelling. For many, physical therapy for neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 also supports balance, endurance, and day-to-day mobility.
Occupational therapy helps with fine motor skills, hand use, dressing, bathing, and other daily tasks that may become harder when joints are inflamed. Therapists may also suggest braces, splints, or adaptive tools to make activities safer and less tiring.
Some children need speech therapy for communication delays, oral motor skills, or trouble coordinating swallowing. Feeding support can also help if eating is slow, tiring, or linked with poor weight gain.
Your genes may have an impact on how drugs work for you
For people living with neonatal-onset severe multisystem inflammatory disease with high IL-18, the exact inherited change causing the illness can shape which immune-calming treatment is most likely to help and how well it works. In day-to-day life, this can mean one baby improves clearly with a medicine that blocks a specific inflammation signal, while another may need a different targeted treatment or a combination approach because the same drug does not control the fevers, rash, bowel problems, or organ inflammation well enough. These genetic differences are also one reason doctors may use genetic test results to help guide treatment choices and close follow-up, especially in such a rare and severe condition.
Pharmacological treatments
Treatment for Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 usually aims to calm dangerous inflammation quickly and then keep it under better control over time. Many living with this condition need care from specialists because symptoms can change fast, especially during severe flares or episodes that look like macrophage activation syndrome. Not everyone responds to the same medication in the same way, so treatment is often adjusted based on symptoms, lab results, and side effects.
Anakinra and canakinumab are often used to reduce inflammation and are among the main medicines tried in this disorder. Anakinra is a daily injection, while canakinumab is longer-acting, and some people improve more with one than the other.
Corticosteroids such as prednisone, prednisolone, methylprednisolone, or dexamethasone can quickly suppress severe inflammation. They are often used during major flares or when early symptoms of macrophage activation syndrome appear, but long-term use is limited by side effects.
Cyclosporine and tacrolimus may be added when inflammation is hard to control or when macrophage activation is a concern. These medicines damp down overactive immune signaling, but they need close monitoring for kidney effects, blood pressure changes, and drug levels.
In some cases, medicines that target related immune pathways may be considered, such as IL-18 blockade with tadekinig alfa or interferon-γ blockade with emapalumab. These options are more specialized and are usually considered in expert centers when standard treatment has not worked well enough.
Genetic influences
Neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 is a rare genetic condition linked to harmful changes in the NLRC4 gene, which helps control one of the body’s key inflammation signals. In this disorder, that signal can become overactive, driving very high IL-18 levels and inflammation across several organs soon after birth. Many living with this condition are the first in their family to have it because the gene change can arise new in the child, but it can also be inherited in an autosomal dominant pattern, which means one altered copy is enough to cause disease. Genetic testing can often confirm neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 and may help doctors identify other family members who could be at risk. Understanding whether a condition is inherited can guide next steps, including genetic counseling and family planning.
Is Neonatal-onset severe multisystemic autoinflammatory disease with increased il18 genetic?
Genetics are central to Neonatal-onset severe multisystemic autoinflammatory disease with increased il18, which is caused by harmful changes in a single gene. These genetic variations disrupt immune control and are key for confirming the diagnosis and family counseling.
Having a genetic risk is not necessarily a diagnosis
Changes in genes are a normal part of human biology and are common in the general population. Most of these changes do not directly affect health and simply reflect natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some cases, though, a single well-understood variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
When a baby has repeated fevers, severe inflammation, and illness affecting several organs, finding the gene change behind neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 can help doctors choose treatment faster and avoid relying only on trial and error. These genetic changes can keep part of the immune system stuck in an “on” state, so medicines that block inflammatory signals, especially IL-1 and sometimes IL-18, may be more useful than treatments aimed at infection alone. The exact variant, how severe the inflammation is, and whether the liver, gut, blood counts, or other organs are affected can all influence which drug is tried first and how closely it is monitored. Genetics is only one factor, and age, weight, organ function, and past medicine response still matter a great deal, especially in newborns and infants. For many families, genetic testing for neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 helps explain why one child may need very targeted immune treatment while another needs a different combination or dose.
Interactions with other conditions
For many living with neonatal-onset severe multisystemic autoinflammatory disease with increased IL18, the biggest concern is not just the daily inflammation but how it can collide with other illnesses. This condition can overlap with episodes of extreme immune overactivation, sometimes called macrophage activation syndrome or HLH, which can look a lot like a severe infection and needs urgent medical care. Having more than one diagnosis can make symptoms feel harder to untangle, especially if fever, rash, diarrhea, or liver problems suddenly worsen and it is not clear whether the cause is a flare, an infection, or both. Some people with this disease also have inflammatory problems in the gut, joints, skin, or liver, so doctors often monitor for conditions that resemble inflammatory bowel disease or hepatitis-like inflammation. Because treatment may involve medicines that lower immune activity, care teams also watch closely for infections and for how other conditions or medicines might affect the overall treatment plan.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Neonatal-onset severe multisystemic autoinflammatory disease with increased il18?
Doctors may first need to rule out serious infections in a newborn, because fever, rash, poor feeding, and signs of body-wide inflammation can look very similar. A dangerous immune overreaction called HLH, along with other rare inherited inflammatory conditions such as cryopyrin-associated disease or mevalonate kinase deficiency, can also overlap and may need special testing to tell apart.
History
For families affected by neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18, the history of the condition is fairly recent. This disorder first came to medical attention when doctors described newborns and very young infants with overwhelming inflammation affecting several parts of the body at once, often including the gut, skin, blood, and immune system. In day-to-day life, this could look like a baby who is critically unwell soon after birth, with persistent fever, severe diarrhea, poor feeding, swelling, or signs of serious inflammation that do not fit a typical infection.
At first, these children were usually recognized by their symptoms rather than by a single unifying diagnosis. Some were initially thought to have unusual infections, immune problems, or other inflammatory illnesses because the early symptoms of neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 can overlap with more familiar conditions. In recent decades, awareness has grown as specialists in immunology, rheumatology, and genetics began to connect similar cases and see that this was part of a distinct group of autoinflammatory diseases, where the body’s innate immune system becomes overactive.
As medical science evolved, blood testing helped clarify the picture. Researchers found that many affected infants had strikingly high levels of IL-18, an inflammatory signal in the immune system, which became an important clue and helped separate this condition from other causes of severe illness in newborns. Later, genetic research confirmed that this was a specific inherited inflammatory disorder, although the condition still remains very rare.
That history matters because rare diseases are often recognized slowly, especially when symptoms begin in the newborn period and move quickly. Many living with neonatal-onset severe multisystemic autoinflammatory disease with increased IL-18 are diagnosed only after expert evaluation in a specialized center. Today, doctors understand much more about the condition than they did when the first cases were reported, and that growing knowledge has improved diagnosis, monitoring, and treatment planning for affected children and their families.